Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott To Market I-Stat POC Blood Analyzer Worldwide Under Aug. 4 Alliance

This article was originally published in The Gray Sheet

Executive Summary

Abbott is rounding out its hospital point-of-care testing portfolio and providing I-Stat with access to a worldwide network of direct sales representatives through a long-term sales, marketing and research alliance announced Aug. 4 at the American Association for Clinical Chemistry conference in Chicago.

You may also be interested in...



Abbott Plans R&D, Marketing Investments For i-STAT Following Acquisition

i-STAT will be assured access to Abbott's brain natriuretic peptide (BNP) marker to develop a point-of-care myocardial infarction diagnostic if a proposed $392 mil. merger is approved by i-STAT shareholders

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel